| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Corxel raises $287m as obesity continues to spark investor interest | ||
| Fr | Daiichi Sankyo and AstraZeneca's Enhertu gains NMPA approval for HER2 GEJ | ||
| Do | BMS bets on Janux's novel solid tumour therapy through $850m deal | ||
| Do | US set to officially exit WHO in culmination of Trump's domestic push | ||
| Do | Heart disease and stroke deaths take a downturn, AHA report reveals | ||
| Do | Johnson & Johnson reports 9.1% increase in sales for Q4 2025 | ||
| Do | Opna Bio's OPN-2853 secures FDA's orphan drug status for myelofibrosis | ||
| Mi | Davos26: Trump says tariff threats helped fix US drug pricing 'unfairness' | ||
| Mi | Pfizer and Novavax ink $530m vaccine delivery licensing deal | ||
| Mi | BMS and Microsoft partner for AI-based lung cancer detection | ||
| Mi | Novo Nordisk and Aspect Biosystems advance partnership for diabetes therapies | ||
| Di | Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up | ||
| Di | GSK scoops up RAPT Therapeutics for $2.2bn | ||
| Di | DeepHow introduces PharmaCloud for pharmaceutical manufacturers | ||
| Di | iRegene receives FDA RMAT designation for NouvNeu001 to treat Parkinson's | ||
| Mo | UK's pharma outlook buoyed by trans-Atlantic trade policies | ||
| Mo | Compounder sues Lilly and Novo for suppressing GLP-1RA competition | ||
| Mo | AstraZeneca to acquire China rights for AbelZeta's CAR-T therapy | ||
| Mo | FDA grants Novartis' ianalumab breakthrough therapy status for Sjögren's disease | ||
| 16.01. | FDA prevails over EMA in 2025 novel drug approvals | ||
| 16.01. | J&J's Caplyta doubles remission rate in MDD patients | ||
| 16.01. | UK's MHRA gives high-dose Wegovy the go-ahead in obesity | ||
| 16.01. | InterAx and Alveus collaborate on small-molecule metabolic treatment | ||
| 16.01. | Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal | ||
| 15.01. | JPM26: Fujifilm's modular manufacturing answer to pharma tariffs |